Wheel vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wheel is a telehealth infrastructure company providing the clinician network, technology, and operations that companies need to build and scale virtual care programs.
About
Wheel is a telehealth infrastructure company founded in 2017 that provides the clinical workforce, technology platform, and operational services that enable businesses to build and power virtual care programs. The company operates as a B2B platform serving healthcare companies, retailers, insurers, and employers that want to offer telehealth services without building a clinical workforce from scratch. Wheel provides access to a nationwide network of licensed clinicians including physicians, nurse practitioners, and physician assistants who can be deployed to power telehealth products across medical, behavioral health, and chronic care specialties. The platform handles clinician credentialing, scheduling, documentation workflows, and state licensure management so that clients can focus on patient experience and growth. Wheel raised over $160M and has powered telehealth programs for companies including retailers launching pharmacy and health clinics and digital health companies scaling their clinical capacity rapidly. As telehealth has become embedded in mainstream healthcare delivery, Wheel enables organizations to participate in virtual care without the complexity of building clinical operations infrastructure internally.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.